

# Omar Y Mian

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6287816/publications.pdf>

Version: 2024-02-01

51  
papers

1,007  
citations

430874

18  
h-index

454955

30  
g-index

51  
all docs

51  
docs citations

51  
times ranked

2041  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice. <i>Molecular and Cellular Biochemistry</i> , 2005, 273, 25-32.	3.1	125
2	Circulating transcriptome reveals markers of atherosclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 3423-3428.	7.1	88
3	Molecular Characterization of Neuroendocrine-like Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3908-3920.	7.0	71
4	Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures. <i>Nature Communications</i> , 2020, 11, 2393.	12.8	60
5	Serial Analysis of Gene Expression. <i>Circulation Research</i> , 2002, 91, 565-569.	4.5	52
6	Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. <i>Clinical Cancer Research</i> , 2019, 25, 210-221.	7.0	48
7	GSTP1 Loss results in accumulation of oxidative DNA base damage and promotes prostate cancer cell survival following exposure to protracted oxidative stress. <i>Prostate</i> , 2016, 76, 199-206.	2.3	45
8	Atherosclerotic Plaque Macrophage Transcriptional Regulators Are Expressed in Blood and Modulated by Tristetraprolin. <i>Circulation Research</i> , 2006, 98, 1282-1289.	4.5	43
9	Methyl-Binding Domain Protein 2â€™-Dependent Proliferation and Survival of Breast Cancer Cells. <i>Molecular Cancer Research</i> , 2011, 9, 1152-1162.	3.4	40
10	Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation. <i>Clinical Cancer Research</i> , 2016, 22, 3310-3319.	7.0	37
11	A Therapeutic Strategy for Preferential Targeting of <i>TET2</i> -Mutant and TET Dioxygenaseâ€™-Deficient Cells in Myeloid Neoplasms. <i>Blood Cancer Discovery</i> , 2021, 2, 146-161.	5.0	36
12	Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy. <i>Journal of Urology</i> , 2019, 202, 710-716.	0.4	31
13	Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy. <i>Journal of Urology</i> , 2022, 207, 541-550.	0.4	30
14	Management Options in Locally Advanced Pancreatic Cancer. <i>Current Oncology Reports</i> , 2014, 16, 388.	4.0	29
15	Chapter 4 The Role of the Epigenetic Signal, DNA Methylation, in Gene Regulation During Erythroid Development. <i>Current Topics in Developmental Biology</i> , 2008, 82, 85-116.	2.2	23
16	Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings. <i>European Radiology</i> , 2019, 29, 4861-4870.	4.5	23
17	Ten-Year Outcomes of Moderately Hypofractionated (70Â°Cy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 325-333.	0.8	23
18	Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response. <i>Npj Precision Oncology</i> , 2018, 2, 14.	5.4	22

#	ARTICLE	IF	CITATIONS
19	An image-guidance system for dynamic dose calculation in prostate brachytherapy using ultrasound and fluoroscopy. <i>Medical Physics</i> , 2014, 41, 091712.	3.0	18
20	The human sodium-dependent ascorbic acid transporters SLC23A1 and SLC23A2 do not mediate ascorbic acid release in the proximal renal epithelial cell. <i>Physiological Reports</i> , 2013, 1, e00136.	1.7	15
21	Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 262-268.	1.6	15
22	Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low-dose rate brachytherapy monotherapy. <i>Brachytherapy</i> , 2020, 19, 43-50.	0.5	15
23	Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	15
24	The Nexus of Endocrine Signaling and Cancer: How Steroid Hormones Influence Genomic Stability. <i>Endocrinology</i> , 2021, 162, .	2.8	14
25	Phase II Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma and Desmoplastic Small Round Cell Tumor. <i>Clinical Cancer Research</i> , 2022, 28, 1773-1782.	7.0	11
26	Computed tomography imaging assessment of postexternal beam radiation changes of the liver. <i>Future Oncology</i> , 2016, 12, 2729-2739.	2.4	9
27	Current and Future Applications of SAGE to Cardiovascular Medicine. <i>Trends in Cardiovascular Medicine</i> , 2003, 13, 163-168.	4.9	8
28	Intraoperative Registered Ultrasound and Fluoroscopy (iRUF) for dose calculation during prostate brachytherapy: Improved accuracy compared to standard ultrasound-based dosimetry. <i>Radiotherapy and Oncology</i> , 2017, 124, 61-67.	0.6	8
29	Reductions in prostatic doses are associated with less acute morbidity in patients undergoing Pd-103 brachytherapy: Substantiation of the rationale for focal therapy. <i>Brachytherapy</i> , 2018, 17, 313-318.	0.5	7
30	The evolving role of molecular profiling in prostate cancer: basal and luminal subtyping transcends tissue of origin. <i>Translational Cancer Research</i> , 2017, 6, S1441-S1445.	1.0	6
31	Prevalence of Substance Use in Patients With Cancer Receiving Radiation Therapy. <i>Clinical Journal of Oncology Nursing</i> , 2016, 20, 397-402.	0.6	5
32	Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation therapy. <i>Advances in Radiation Oncology</i> , 2018, 3, 601-610.	1.2	5
33	Analysis of the 2017 American Society for Radiation Oncology (ASTRO) Research Portfolio. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 297-304.	0.8	5
34	Bladder-sparing treatment of nonmetastatic muscle-invasive bladder cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2019, 17, 697-707.	0.3	5
35	Responses to the 2018 and 2019 "One Big Discovery" Question: ASTRO Membership's Opinions on the Most Important Research Question Facing Radiation Oncology   Where Are We Headed?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 38-40.	0.8	4
36	Current Landscape and Future Directions on Bladder Sparing Approaches to Muscle-Invasive Bladder Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 3.	3.0	3

#	ARTICLE	IF	CITATIONS
37	125I Interstitial brachytherapy with or without androgen deprivation therapy among unfavorable-intermediate and high-risk prostate cancer. <i>Brachytherapy</i> , 2022, 21, 85-93.	0.5	3
38	Management of Oligometastatic Prostate Cancer. <i>Applied Radiation Oncology</i> , 2020, 9, 6-10.	0.5	3
39	Timely stereotactic body radiotherapy (SBRT) for spine metastases using a rapidly deployable automated planning algorithm. <i>SpringerPlus</i> , 2016, 5, 1337.	1.2	2
40	Use of 5-alpha-reductase inhibitors as alternatives to luteinizing-hormone releasing hormone (LHRH) analogs or anti-androgens for prostate downsizing before brachytherapy. <i>Practical Radiation Oncology</i> , 2018, 8, e159-e165.	2.1	1
41	Responses to the 2017 "€1 Million Gray Question" ASTRO Membership's Opinions on the Most Important Research Question Facing Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 249-250.	0.8	1
42	The landscape of early carcinogenesis revealed through the lens of integrative genomics, epigenomics, and transcriptomics. <i>Journal of Thoracic Disease</i> , 2019, 11, 2188-2191.	1.4	1
43	The ASTRO Research Portfolio: Where Do We Go From Here?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 308-309.	0.8	1
44	Therapeutic Targeting of TET-Dioxygenase Deficiency in Myeloid Malignancies. <i>Blood</i> , 2021, 138, 3985-3985.	1.4	1
45	Yes, Nodal Recurrence of Prostate Cancer is Potentially Curable. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 238.	0.8	0
46	Analysis of Spatial Dose-Volume Relationships and Decline in Sexual Function Following Permanent Brachytherapy for Prostate Cancer. <i>Urology</i> , 2020, 135, 111-116.	1.0	0
47	Pre and postradiation lymphopenia predicts survival in management of bone metastases.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9563-9563.	1.6	0
48	Dosimetric predictors of sexual function decline following LDR brachytherapy for prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , 2016, 34, 113-113.	1.6	0
49	The effect of antibiotic use on immune-checkpoint inhibitor efficacy in patients with advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e17116-e17116.	1.6	0
50	A genomic classifier for prostate cancer correlates with adverse pathologic features: Transcriptomic features of cribriform and intraductal carcinoma of the prostate.. <i>Journal of Clinical Oncology</i> , 2022, 40, 268-268.	1.6	0
51	Prognostic factors and clinical outcomes in patients with upper tract urothelial carcinoma undergoing surgery: The Cleveland Clinic experience.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4593-4593.	1.6	0